Cystic fibrosis community
with gating (class III) mutations
can now breathe easy on news of Government subsidy
Australia’s cystic fibrosis community is elated
by the news of expanded PBS subsidy for Kalydeco in people aged 6 years and older who have gating (class III) mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene.
Kalydeco has been approved for PBS subsidy from 01 December 2014 for people 6 years and older who have the following gating mutations: G551D, G178R, S549N,
S549R, G551S, G1244E, S1251N, S1255P, G970R and G1349D. Kalydeco the most important development in the treatment of the disease since the discovery of the cystic fibrosis gene in 1989 works by ‘turning off’ the genetic defect that causes cystic fibrosis, allowing the body to break down and drain mucus in the lungs and digestive system.KALYDECO will be listed on the PBS under section 100, Complex Authority Required Highly Specialised Drugs Program
* People must be aged six years and older to receive Kalydeco.